Drug Profile
KiroVAX 004
Alternative Names: KiroVAX-004; TAPA pulsed dendritic cell vaccine - KiroVAX-004Latest Information Update: 27 Oct 2020
Price :
$50
*
At a glance
- Originator Kiromic
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 27 Oct 2020 No development reported - Phase-I/II for Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (SC)
- 18 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02705703)
- 07 Mar 2016 Preclinical trials in Solid tumours in USA (SC), before March 2016